These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11909985)

  • 1. Relevance of motor complications in Parkinson's disease.
    Adler CH
    Neurology; 2002 Feb; 58(4 Suppl 1):S51-6. PubMed ID: 11909985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries.
    Hechtner MC; Vogt T; Zöllner Y; Schröder S; Sauer JB; Binder H; Singer S; Mikolajczyk R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):969-74. PubMed ID: 24953743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical Management and Prevention of Motor Complications in Parkinson's Disease.
    Aradi SD; Hauser RA
    Neurotherapeutics; 2020 Oct; 17(4):1339-1365. PubMed ID: 32761324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2017 Oct; 18(14):1457-1465. PubMed ID: 28847181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
    Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
    Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmaceutical care for Parkinson's patients with orthostatic dysregulation].
    Schulte S; Annicotte I; Mowitz A; Zerres M; Braun U; Joeres U; Jaehde R
    Med Monatsschr Pharm; 2011 Jul; 34(7):250-6. PubMed ID: 21809600
    [No Abstract]   [Full Text] [Related]  

  • 9. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dyskinesias of the tongue and other face structures].
    Lewandowski L; Osmola K; Grodzki J
    Ann Acad Med Stetin; 2006; 52 Suppl 3():61-3. PubMed ID: 17939202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Freezing of gait unresponsive to dopaminergic stimulation in patients with severe Parkinsonism].
    Vaamonde Gamo J; Cabello JP; Gallardo Alcañiz MJ; Flores Barragan JM; Carrasco García de León S; Ibañez Alonso RE
    Neurologia; 2010; 25(1):27-31. PubMed ID: 20388458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.